338 related articles for article (PubMed ID: 18946750)
1. Current topics and perspectives relating to hormone therapy for prostate cancer.
Suzuki H; Kamiya N; Imamoto T; Kawamura K; Yano M; Takano M; Utsumi T; Naya Y; Ichikawa T
Int J Clin Oncol; 2008 Oct; 13(5):401-10. PubMed ID: 18946750
[TBL] [Abstract][Full Text] [Related]
2. Safety of antiandrogen therapy for treating prostate cancer.
Ricci F; Buzzatti G; Rubagotti A; Boccardo F
Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
[TBL] [Abstract][Full Text] [Related]
3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
4. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
5. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
Kojima S; Suzuki H; Akakura K; Shimbo M; Ichikawa T; Ito H
J Urol; 2004 Feb; 171(2 Pt 1):679-83. PubMed ID: 14713785
[TBL] [Abstract][Full Text] [Related]
6. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
7. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
8. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in hormonal therapy for advanced prostate cancer.
Oottamasathien S; Crawford ED
Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
[TBL] [Abstract][Full Text] [Related]
10. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
[TBL] [Abstract][Full Text] [Related]
11. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
Tsukamoto S; Akaza H
Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
[TBL] [Abstract][Full Text] [Related]
12. [Anti-androgen withdrawal syndrome].
Breul J; Paul R
Urologe A; 1998 Mar; 37(2):156-8. PubMed ID: 9563126
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
15. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA; Virgo KS; Nam R; Somerfield MR; Ben-Josef E; Mendelson DS; Middleton R; Sharp SA; Smith TJ; Talcott J; Taplin M; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
J Clin Oncol; 2007 Apr; 25(12):1596-605. PubMed ID: 17404365
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of hormone therapy in advanced prostate cancer.
Dreicer R
Cleve Clin J Med; 2000 Oct; 67(10):720-2, 725-6. PubMed ID: 11060958
[TBL] [Abstract][Full Text] [Related]
17. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
Ryan CJ; Small EJ
Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
[TBL] [Abstract][Full Text] [Related]
18. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
Scherr DS; Pitts WR
J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
[TBL] [Abstract][Full Text] [Related]
19. Controversies in the management of advanced prostate cancer.
Tyrrell CJ
Br J Cancer; 1999 Jan; 79(1):146-55. PubMed ID: 10408706
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy: historical perspective to future directions.
Mcleod DG
Urology; 2003 Feb; 61(2 Suppl 1):3-7. PubMed ID: 12667881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
